Spyre Therapeutics News

Spyre Therapeutics | 8-K: Current report

Nov 19 17:16 ET

Spyre Therapeutics | 424B5: Prospectus

Nov 19 16:42 ET

Spyre Therapeutics | 424B5: Prospectus

Nov 18 17:15 ET

Spyre Therapeutics | 10-Q/A: Quarterly report (Amendment)

Nov 18 16:15 ET

Spyre Therapeutics | 10-Q/A: Quarterly report (Amendment)

Nov 18 16:12 ET

Spyre Therapeutics | 10-Q/A: Quarterly report (Amendment)

Nov 18 16:11 ET

Spyre Therapeutics | 10-K/A: Annual report (Amendment)

Nov 18 16:10 ET

Spyre Therapeutics | 8-K: Current report

Nov 18 16:06 ET

Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Venrock Healthcare Capital Partners III, L.P.(5.3%),VHCP Co-Investment Holdings III, LLC(5.3%), etc.

Nov 14 17:55 ET

Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Perceptive Advisors LLC(5.7%),Joseph Edelman(5.7%), etc.

Nov 14 16:41 ET

Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Commodore Capital LP(3.9%),Commodore Capital Master LP(3.9%)

Nov 14 16:13 ET

Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Deep Track Capital, LP(1.97%),Deep Track Biotechnology Master Fund, Ltd.(1.97%), etc.

Nov 14 09:47 ET

Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Avoro Capital Advisors LLC(1.7%),Behzad Aghazadeh(1.7%)

Nov 14 09:37 ET

Spyre Therapeutics | 8-K: Current report

Nov 12 12:58 ET

Spyre Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-FMR LLC(14.999%),Abigail P. Johnson(14.999%)

Nov 12 10:41 ET

Spyre Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Albers Jeffrey W.

Nov 8 17:00 ET

Spyre Therapeutics | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(5.2%)

Nov 8 14:28 ET

Spyre Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Nov 7 16:23 ET

Spyre Therapeutics | 8-K: Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7 16:09 ET

Spyre Therapeutics | 10-Q: Q3 2024 Earnings Report

Nov 7 16:05 ET